Transformation of the list of vital and essential medicines in 2009 2023

Abstract


One of the main problems of drug provision is to maintain a balance between the needs of patients and the resource capabilities of the system, as well as the formation of the most effective strategy for their use. Increasing the availability of medicines to the population is carried out, among other things, through state price regulation. This paper examines changes in the list of vital and essential medicines (VED) approved by the Government of the Russian Federation for the purpose of state regulation of drug prices, in terms of INN, the volume of purchases of the VED segment and the dynamics of the average cost per package of VED in 2009 2023.

About the authors

Maria N. Denisova

N. A. Semashko National Research Institute of Public Health, Moscow, Russian Federation

Email: m.denisova@nriph.ru

Anastasia A. Sinitsyna

N. A. Semashko National Research Institute of Public Health, Moscow, Russian Federation; I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Email: sinitsyna_a_a@staff.sechenov.ru

Ernest G. Naneishvili

I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia

Email: ernestnaneishvili@gmail.com

References

  1. Zvirko SE. The system of state regulation and pricing control in the UK: legislative and institutional aspect. Theoretical and applied economics. 2018;(2):22—38. doi: 10.25136/2409—8647.2018.2.26594 (In Russ.)
  2. Antsiferova EK. The list of the ZHNVLP as one of the institutions of social protection of the population in the Russian Federation. In: Constitutional legal regulation of social relations: theory, methodology, practice: materials of the International Scientific and Practical Conference, Voronezh, January 25, 2018. Voronezh; 2018:177—184. (In Russ.)
  3. Sura MV, Omel’yanovskij VV. Evolution of the expertise system for the development of Vital and Essential Drug List. Medical technologies. Assessment and choice. 2011;(3):30—33.
  4. Trofimova EO, Denisova MN, Orlov AS. Development of the Russian pharmaceutical market: index analysis. Pharmacy. 2019;68(6):5—10. DOI: 10/29296/25419218-2019-06-01

Statistics

Views

Abstract - 7

PDF (Russian) - 3

Cited-By


PlumX

Dimensions


Copyright (c) 2025 АО "Шико"

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Mailing Address

Address: 105064, Moscow, st. Vorontsovo Pole, 12, building 1

Email: redactor@remedium-journal.ru

Phone: +7(495) 917-48-86



Principal Contact

Sherstneva Elena Vladimirovna
EXECUTIVE SECRETARY
FSSBI «N.A. Semashko National Research Institute of Public Health»

105064, Vorontsovo Pole st., 12, Moscow


Email: redactor@remedium-journal.ru

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies